Clinical Trials

Inclusion Criteria

1. Male or female age ≥ 18 years.
2. Eastern Cooperative Oncology Group (ECOG) performance status ≤
3. Histologically confirmed advanced solid malignancy.
4. Will be starting on ICIs.

• For cohort 1: Ipilimumab with or without anti-PD-1/PD-L1 including but not limited to pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab, or durvalumab.
• For cohort 2: Anti-PD-1/PD-L1 described above with or without chemotherapy.

5. Patients must have adequate organ and marrow function as defined below:

• Absolute neutrophil count (ANC) ≥ 1000/mm3
• Platelet count ≥ 75,000/mm3
• Hemoglobin ≥ 9.0 g/dL
• Creatinine ≤ 2 x ULN
• SGOT (AST) ≤ 2 x ULN
• Albumin ≥ 3 g/dL

6. Willing and able to provide research stool and blood samples.
7. Negative serum pregnancy test done ≤ 7 days prior to enrollment, for women of childbearing potential only.
8. Capable of providing valid informed consent.
9. Willing to return to enrolling institution for all study visits (blood draws, etc).

Exclusion Criteria 

1. Requires prolonged systemic antibiotic therapy for other condition and recent systemic antibiotic within the past 2 weeks
2. Fecal microbiota transplant (FMT) within the past 6 months
3. FMT with an associated serious adverse event related to the FMT product or procedure.
4. Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of over-the-counter probiotics.
5. Immunocompromised patients including patients known to be HIV positive or those on chronic steroids > 20 mg prednisone a day or prednisone-equivalent. Note: Must be off systemic steroids at least 90 days prior to enrollment. However, topical steroids, inhalants or steroid eye drops are permitted.
6. History of inflammatory bowel disease (IBD), e.g., ulcerative colitis, Crohn’s disease, or microscopic colitis.
7. History of chronic diarrhea.
8. History of celiac disease.
9. Currently has a colostomy.
10. Intraabdominal surgery related to gastrointestinal tract within the last 60 days.
11. Evidence of active, severe colitis.
12. History of short gut syndrome or motility disorders.
13. Requires the regular use of medications to manage bowel hypermotility.
14. Active autoimmune disease that has required systemic treatment in the ≤ 30 days (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs) prior to randomization. Note: Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment. Patients with vitiligo, Graves’ disease, or psoriasis not requiring systemic treatment within the past 30 days are not excluded.